ES2168287T3 - Vacuna capaz de provocar una respuesta inmunitaria contra los gangliosidos n-glicolados y su aplicacion anti-cancerosa. - Google Patents
Vacuna capaz de provocar una respuesta inmunitaria contra los gangliosidos n-glicolados y su aplicacion anti-cancerosa.Info
- Publication number
- ES2168287T3 ES2168287T3 ES94203736T ES94203736T ES2168287T3 ES 2168287 T3 ES2168287 T3 ES 2168287T3 ES 94203736 T ES94203736 T ES 94203736T ES 94203736 T ES94203736 T ES 94203736T ES 2168287 T3 ES2168287 T3 ES 2168287T3
- Authority
- ES
- Spain
- Prior art keywords
- gangliosids
- immune response
- vaccine
- glicolated
- cancerose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
EL INVENTO PROPORCIONA NUEVOS USOS PARA GANGLIOSIDOS N GLICOLILADAS, O DERIVADOS Y/O OLIGOSACARIDOS DEL MISMO. EL INVENTO PROPORCIONA ADEMAS METODOS PARA OBTENER TALES GANGLIOSIDOS, ASI COMO COMPOSICIONES DE VACUNA QUE COMPRENDEN DICHOS GANGLIOSIDOS. LOS GANGLIOSIDES SE PUEDEN UNIR A PORTADORES Y SE PUEDEN ACOMPAÑAR POR ADYUGANTES. LAS COMPOSICIONES DE VACUNA SE PUEDEN EMPLEAR EN EL TRATAMIENTO DE CANCERES DE PECHO, POR LO QUE LAS GANGLIOSIDOS SE EMPLEAN PARA OBTENER UNA RESPUESTA INMUNE A LOS GANGLIOSIDOS CORRESPONDIENTES DE CELULAS TUMOROSAS DE PECHO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU92131A CU22420A1 (es) | 1993-12-29 | 1993-12-29 | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2168287T3 true ES2168287T3 (es) | 2002-06-16 |
Family
ID=45992881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94203736T Expired - Lifetime ES2168287T3 (es) | 1993-12-29 | 1994-12-22 | Vacuna capaz de provocar una respuesta inmunitaria contra los gangliosidos n-glicolados y su aplicacion anti-cancerosa. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5788985A (es) |
EP (1) | EP0661061B1 (es) |
JP (1) | JP3044173B2 (es) |
CN (2) | CN1099894C (es) |
CA (1) | CA2139217C (es) |
CU (1) | CU22420A1 (es) |
DE (1) | DE69428969T2 (es) |
ES (1) | ES2168287T3 (es) |
HK (1) | HK1048942A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22702A1 (es) * | 1997-10-21 | 2001-07-31 | Centro Inmunologia Molecular | Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
US5612030A (en) | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
AUPO732997A0 (en) * | 1997-06-12 | 1997-07-03 | Csl Limited | Ganglioside immunostimulating complexes and uses thereof |
US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
WO2001081371A1 (fr) | 2000-04-25 | 2001-11-01 | Otsuka Pharmaceutical Co., Ltd. | Peptides gd3 mimetiques |
PE20020572A1 (es) | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
CU23257A1 (es) | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
ES2581523T3 (es) | 2009-09-01 | 2016-09-06 | Lz Therapeutics, Inc. | Producción en cultivo celular (no bovino, no porcino) de GM1 |
WO2011146804A2 (en) * | 2010-05-20 | 2011-11-24 | Lazarus Therapeutics, Inc. | Gm3 ganglioside replacement therapy |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
US9556467B2 (en) | 2012-01-20 | 2017-01-31 | Garnet Bio Therapeutics, Inc. | Methods of ganglioside production |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727136A (en) * | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
US4965198A (en) * | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
WO1987006840A1 (en) * | 1986-05-07 | 1987-11-19 | Sloan-Kettering Institute For Cancer Research | Vaccine for stimulating or enhancing production of antibodies directed against gm2 |
NZ222192A (en) * | 1986-10-20 | 1991-03-26 | Kanto Ishi Pharma Co Ltd | Glycolipid containing n-glycolylneuraminic acid, and preparation thereof |
US4849509A (en) * | 1987-02-20 | 1989-07-18 | The Wistar Institute | Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies |
US5026557A (en) * | 1987-09-09 | 1991-06-25 | The Liposome Company, Inc. | Adjuvant composition |
US5102663A (en) * | 1988-10-18 | 1992-04-07 | Sloan-Kettering Instutute For Cancer Research | Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3 |
ATE243713T1 (de) * | 1989-05-25 | 2003-07-15 | Sloan Kettering Inst Cancer | Antiidiotypischer antikörper, der ein immunantwort gegen ein glykosphingolipid induziert und seine verwendung |
EP0630260B1 (en) * | 1991-03-12 | 2001-01-24 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Polysaccharide-protein conjugates |
ATE188874T1 (de) * | 1992-08-18 | 2000-02-15 | Centro Inmunologia Molecular | Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen |
NZ261744A (en) * | 1993-01-22 | 1997-03-24 | Sloan Kettering Inst Cancer | Ganglioside-klh conjugate vaccines with qs-21 |
-
1993
- 1993-12-29 CU CU92131A patent/CU22420A1/es unknown
-
1994
- 1994-12-22 ES ES94203736T patent/ES2168287T3/es not_active Expired - Lifetime
- 1994-12-22 DE DE69428969T patent/DE69428969T2/de not_active Expired - Lifetime
- 1994-12-22 EP EP94203736A patent/EP0661061B1/en not_active Expired - Lifetime
- 1994-12-28 CN CN94113506A patent/CN1099894C/zh not_active Expired - Lifetime
- 1994-12-28 CA CA002139217A patent/CA2139217C/en not_active Expired - Lifetime
- 1994-12-28 JP JP6328669A patent/JP3044173B2/ja not_active Expired - Lifetime
- 1994-12-29 US US08/365,684 patent/US5788985A/en not_active Expired - Lifetime
-
2001
- 2001-12-25 CN CN01144023A patent/CN1371690A/zh active Pending
-
2003
- 2003-02-18 HK HK03101194.9A patent/HK1048942A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JPH0853366A (ja) | 1996-02-27 |
CN1371690A (zh) | 2002-10-02 |
CA2139217A1 (en) | 1995-06-30 |
CN1099894C (zh) | 2003-01-29 |
JP3044173B2 (ja) | 2000-05-22 |
DE69428969D1 (de) | 2001-12-13 |
EP0661061A3 (en) | 1996-12-04 |
DE69428969T2 (de) | 2002-08-22 |
CN1122247A (zh) | 1996-05-15 |
CA2139217C (en) | 2001-08-07 |
HK1048942A1 (zh) | 2003-04-25 |
EP0661061B1 (en) | 2001-11-07 |
EP0661061A2 (en) | 1995-07-05 |
CU22420A1 (es) | 1996-01-31 |
US5788985A (en) | 1998-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2168287T3 (es) | Vacuna capaz de provocar una respuesta inmunitaria contra los gangliosidos n-glicolados y su aplicacion anti-cancerosa. | |
AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
ES2152222T3 (es) | Sulfonamidas, su preparacion y su uso como medicamento e intermedio. | |
ES2113881T3 (es) | Derivados y analogos de acido 2-desoxi-2,3-didehidro-n-acetil neuraminico y su utilizacion como agentes antivirales. | |
MX9203385A (es) | Derivados de taxol y composiciones farmaceuticas que los contienen. | |
UY26456A1 (es) | Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen. | |
ES2054716T3 (es) | Bis-naftalimidas, su obtencion y empleo. | |
MX9308013A (es) | 4-fenil-piridonas y 4-fenil-2-fenil-2-alcoxipiridinas sustituidas, procedimiento para su preparacion y medicamentos que los contienen. | |
UY37669A (es) | Conjugados de fármaco-anticuerpo (adc) anti-prlr y usos de los mismos | |
AR013001A1 (es) | Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina. | |
MX17808A (es) | Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos | |
CO2021015184A2 (es) | Conjugados de anticuerpo y fármaco | |
BR112015024621A8 (pt) | usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi | |
AR115081A1 (es) | Aislados de microbacterias y sus usos | |
BR112015026077A8 (pt) | barra de sabão, método de redução de bactérias gram positivas e uso de uma barra de sabão | |
CO2022003742A2 (es) | Conjugados de interleuquina 10 y sus usos | |
MX9302487A (es) | Piridonas sustituidas por bifenilmetilo, procedimiento para su obtencion y medicamentos que las contienen. | |
ES2052484T1 (es) | N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
AR015956A1 (es) | Composiciones de citoquinas oromucosales y usos de las mismas | |
BR112022000364A2 (pt) | Sistemas fluorescentes para imagiologia biológica e seus usos | |
ES2172558T3 (es) | Lubricante compatible con radiaciones para dispositivos medicos. | |
MX5649E (es) | Procedimiento microbiologico para producir el polisacarido m-30-c | |
CL2021003228A1 (es) | Compuestos tricíclicos y su uso | |
AR120316A1 (es) | Aislados microbacterianos y sus usos | |
ES2054790T3 (es) | Compuestos que tienen actividad cardiovascular. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 661061 Country of ref document: ES |